Boehringer Ingelheim Ltd. and IBM Canada plan to explore the use of blockchain technology in clinical trials. This collaboration marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.  Based on the findings of regulatory authorities, processes to ensure the quality of clinical trials are frequently inadequate, and clinical trial records are often erroneous or incomplete, which may put patient safety and interpretability of trials at risk. Th...